CA3009850C - Composes deuteres pour le traitement du cancer et de maladies et troubles associes, et compositions et methodes associees - Google Patents

Composes deuteres pour le traitement du cancer et de maladies et troubles associes, et compositions et methodes associees Download PDF

Info

Publication number
CA3009850C
CA3009850C CA3009850A CA3009850A CA3009850C CA 3009850 C CA3009850 C CA 3009850C CA 3009850 A CA3009850 A CA 3009850A CA 3009850 A CA3009850 A CA 3009850A CA 3009850 C CA3009850 C CA 3009850C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutical composition
formula
cancer
osimertinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3009850A
Other languages
English (en)
Other versions
CA3009850A1 (fr
Inventor
Huang CHAORAN
Cheng CHANGFU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuform Pharmaceuticals Inc
Original Assignee
Neuform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuform Pharmaceuticals Inc filed Critical Neuform Pharmaceuticals Inc
Publication of CA3009850A1 publication Critical patent/CA3009850A1/fr
Application granted granted Critical
Publication of CA3009850C publication Critical patent/CA3009850C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux composés chimiques utiles pour traiter le cancer, ou une maladie ou un trouble associé au cancer, ainsi qu'une composition pharmaceutique contenant ces composés, et des procédés de préparation et d'utilisation de ceux-ci.
CA3009850A 2015-12-27 2016-12-23 Composes deuteres pour le traitement du cancer et de maladies et troubles associes, et compositions et methodes associees Active CA3009850C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562271275P 2015-12-27 2015-12-27
US62/271,275 2015-12-27
US201662330810P 2016-05-02 2016-05-02
US62/330,810 2016-05-02
PCT/US2016/068585 WO2017117070A1 (fr) 2015-12-27 2016-12-23 Composés deutérés pour le traitement du cancer et de maladies et troubles associés, et compositions et méthodes associées

Publications (2)

Publication Number Publication Date
CA3009850A1 CA3009850A1 (fr) 2017-07-06
CA3009850C true CA3009850C (fr) 2020-05-26

Family

ID=59225711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3009850A Active CA3009850C (fr) 2015-12-27 2016-12-23 Composes deuteres pour le traitement du cancer et de maladies et troubles associes, et compositions et methodes associees

Country Status (8)

Country Link
US (1) US9968606B2 (fr)
EP (1) EP3394047B1 (fr)
JP (1) JP6605751B2 (fr)
KR (1) KR102029135B1 (fr)
CN (1) CN108779102B (fr)
AU (1) AU2016380190B2 (fr)
CA (1) CA3009850C (fr)
WO (1) WO2017117070A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CN108047205B (zh) * 2016-12-14 2019-08-27 河南真实生物科技有限公司 2-(2，4，5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
CN107629039B (zh) * 2017-10-12 2019-09-20 河南真实生物科技有限公司 氘代丙烯酰胺的制备方法和中间体
CN108675993A (zh) * 2018-06-14 2018-10-19 纽瑞森生物科技（北京）有限公司 氘代嘧啶类化合物、制备方法、药物组合物、制剂和用途
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b
EA202100252A1 (ru) * 2019-04-09 2022-03-10 Хэнань Дженьюин Биотек Ко., Лтд. Производная 2-(2,4,5-замещенного фениламино)пиримидина и его кристаллическая форма "в"
CN112684026B (zh) * 2020-12-04 2022-05-17 中山奕安泰医药科技有限公司 一种奥希替尼中间体纯度的检测方法
CN113582976B (zh) * 2021-08-24 2023-03-17 郑州大学 氘代2-取代苯胺-4-吲哚基嘧啶类衍生物及其制备方法和应用
KR102556500B1 (ko) 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104140418B (zh) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
CN105237515B (zh) * 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105153122B (zh) * 2015-08-27 2018-07-20 上海圣考医药科技有限公司 [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
KR101848147B1 (ko) 2016-07-14 2018-04-11 건양대학교산학협력단 세포 투과성 hoxa9 융합단백질 및 이를 포함하는 폐암의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN108779102B (zh) 2020-04-21
AU2016380190B2 (en) 2019-03-14
EP3394047A1 (fr) 2018-10-31
AU2016380190A1 (en) 2018-08-09
KR20180090899A (ko) 2018-08-13
AU2016380190A8 (en) 2018-08-16
CA3009850A1 (fr) 2017-07-06
EP3394047B1 (fr) 2019-12-11
KR102029135B1 (ko) 2019-10-07
CN108779102A (zh) 2018-11-09
WO2017117070A1 (fr) 2017-07-06
WO2017117070A8 (fr) 2018-07-26
JP2019500408A (ja) 2019-01-10
EP3394047A4 (fr) 2018-11-21
US20170368065A1 (en) 2017-12-28
US9968606B2 (en) 2018-05-15
JP6605751B2 (ja) 2019-11-13

Similar Documents

Publication Publication Date Title
CA3009850C (fr) Composes deuteres pour le traitement du cancer et de maladies et troubles associes, et compositions et methodes associees
US10793543B2 (en) Selective C-KIT kinase inhibitor
US10851092B2 (en) Pyridine compound
BR112014025508B1 (pt) forma de sal de um inibidor de histona metiltransferase ezh2 humana
US10899763B2 (en) Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
TWI845819B (zh) 用作激酶抑制劑的化合物及其應用
CN106279160A (zh) N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
WO2022199547A1 (fr) Dérivé de 7,9-dihydropurine et son usage pharmaceutique
AU2016340740B2 (en) Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
CN107501279A (zh) 呋喃并喹啉二酮类化合物及其医药用途
WO2023116895A1 (fr) Polymorphe d'inhibiteur de kras, son procédé de préparation et son utilisation
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
US11801243B2 (en) Bromodomain inhibitors for androgen receptor-driven cancers
CN111039940B (zh) 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途
WO2020043078A1 (fr) Forme de sel et forme cristalline d'un nouveau composé azatricyclique et utilisation associée
US20200354372A1 (en) 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
WO2024211314A2 (fr) Inhibiteurs de chd1l et leurs utilisations
CN104557955B (zh) 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
KR20210147876A (ko) 페닐렌 디벤즈아미드계 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 약제학적 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180626